Introduction
Most Cancers are outlines as the uncontrolled growth of abnormal cells as they cannot be subjected to the check points that can identify and decide whether the cells to divide and differentiate or to die. Thus they build up a level of self-governance from the signs and create uncontrolled development forming tumors.
Cancer can be recognized to defective protein-protein interactions (PPIs), therefore this type of intermolecular event is a highly attractive target in drug discovery. The belief that targeting PPIs is an unsuitable strategy in drug design has been challenged by recent successful cases, such as the development AMG-232, a MDM2-p53 inhibitor, currently in Phase II clinical trials for cancer therapy [1] . Drugs are one of the effective treatments for cancer and they are classified according to their site of action and specific point in the biosynthetic pathways of bio-molecules like cytotoxic antibodies, anti-metabolites, anti-tumor antibodies, plant alkaloids, biological agents and DNA linking agents.
There are numerous drugs available for cancer remedy and most of them inhibit the DNA synthesis or a few other syntheses in the cell growth cycle. There are number of cancerous drugs available for the treatment of cancer like Cycloplasmide a drug used to treat cancers and autoimmune ailment. It is a powerful drug in treating the disease but has been eradicated due to its toxicity. It works by using the T-regulatory cells (CD4+ CD25+ T cells) in naive and tumor benign hosts. And induction of T-cellular boom factors consisting of type 1 IFNS [2] , Cisplastin an intravenous drug that works with the aid of interfering with DNA replication that kills the proliferating cells. After the administration the two chloride ligands are slowly displaced with the aid of the water to shape aqua complicated [3] , Methotrexate a chemotherapy agent and immune device suppressant works by using inhibiting the dihydrofolate reductase that is involved in tetrahydrofolate synthesis this is crucial for purines and pyrimidines synthesis hence inhibiting the synthesis of DNA, RNA and proteins [4] , Vincristine used to treat many cancers like acute lymphocytic leukemia, acute myeloid leukemia works by binding to the tubulin protein stopping the cell from separating its chromosomes during the metaphase then undergoes apoptosis. But an overuse of Vincristine leads to over expression of the P-glycoprotein pump [5] .
Various pigments like Varamine, Violacein, Amphimedine, Fascaplysin, Monascin, Chinikomycin, and so forth were discovered with anticancer activity and the anticancer activity is docked using Glide [6] . Violacein is one such pigment isolated from Chromobacterium violaceum and has diverse biological properties because of its anti leukemic activity that has increased interest owing to its important biological activities and pharmacological potential as an anti-cancerous agent.
It has effectiveness on four types of colon cancer cell lines that cause apoptosis in HC60 leukemic cells that was followed by activation of caspase 8 transcription of nuclear factor Kappa B and p38 MAP kinase activation. Violacein showed a efficiency in number of cell lines in both neoplastic and hematological malignant origins and it is most effective against MOLT-4 leukemia that is found to inhibit the growth and proliferation of colorectal cancer cell lines. The activity is also enhanced by the hypoxia-induced cells [7] and the increase of mitochondrial membrane potential in MRC-5 and HeLa cells also suggests that mitochondrial membrane hyper polarization might be the main cause of cell death triggered by violacein [8] .
Thus the current study is focused on determining the activity of potent dye violacein for its anticancerous activity by using molecular docking techniques.
1.1Drug Discovery
Drug discovery is a process of finding a new medicine for a therapeutic use. One of the most capable methods to find out the new drug is to find out the target protein interactions with randomly chosen compounds that are the part of compound libraries. Thus, the accurate prediction of the binding modes between the ligand and protein is of fundamental importance in modern structure-based drug design. Computer-based molecular modeling aims to speed up drug discoveries by predicting potential effectiveness of ligand-protein interactions. Molecular docking is one such method of a structural based drug design.
Molecular Docking
Molecular docking is a tool that facilitates the structural molecular biology and computer assisted drum design. The aim of this is to identify the major binding modes of the ligand to that of a three dimensional structure. Thus this finds out the intermolecular complex formed between the two molecules [9] . Molecular docking uses the scoring function that can predict the binding strength, complex energy and can also evaluate the binding affinity between the protein and the ligand [10] that may result in the activation or inhibition of the enzyme. because of its ability to predict, degree of accuracy and the conformation of small molecule ligands with the target binding site [11] it is used as a most common method used in drug design. Furthermore molecular docking algorithms also execute rankings of the docked compounds based on the affinity of the ligand-receptor complex [12] . Detailed understanding of the principles that direct the nature of different interactions provide an outline for designing the drug of the therapeutic target. For this a variety of docking methods has been employed. These methods provide a ranking of the ligand and their ability to interact with the target. The optimal binding is measured by the scoring function. During computational docking a pose is generated, scored and compared to the previous pose. This decides the previous pose to be considered or deleted based on the score. This scoring iterates till it achieves to an endpoint and identifies the perfect fit.
Numerous software packages have been developed with the implementation of various molecular docking algorithms based on different search methods [13] . The present work of molecular docking has been done using commercially available software's ArgusLab and SwissDock.
ArgusLab is a molecular modeling, graphics, and drug designing program based on genetic algorithm. It is implemented with exhaustive search methods, the Argus Dock docking engine and AScore scoring function [14] . It is also capable of performing molecular geometry calculations and molecular structure visualization.
SwissDock is a docking web server that can detect the structure of the target protein, as well as that of the ligand automatically prepared for docking and additionally the cumbersome syntax of the docking engine hides a clean web interface that provides reasonable alternative sets of parameters along with sample input files [15] .
II. Materials and Methods

Computational Methodology 2.1.1 Data Set
Three-dimensional (3D) experimentally known protein-ligand complexes were obtained from Brookhaven Protein Data Bank (PDB). Biological databases like PDB(protein data bank), pubchem, drug bank, KEGG (Kyto Encyclopedia of Genes and Genomes) can be used for the same.
Generation of Violacein 3D structure:
ChemSpider server was used for generating 3D structure of violacein (Fig 1) and SMILES notation of violacein was found in chemspider that was used to translate this 3D structure by SMILES translator online server, employing JAVA based structure applet in chemSpider. Then the geometric was reframed using the Universal Force Field (UFF), molecular mechanics and final geometry was performed by Semi empirical Quantum mechanics method (QM). Finally, violacein structure was saved as MOL file for further docking procedure [16] .
Fig 1. 3D structure of violacein using ChemSpider
Collection of cancer effecting proteins and prediction of protein structure similarity:
The cancer effecting proteins were retrieved from the KEGG (Kyoto Encyclopedia of Genes and Genomes) a predominant database for retrieving the information about Cancer path ways. Ten categories of cancer pathways were retrieved from KEGG and most effective were listed. (Table 1 ). Structural similarity of these proteins corresponding to the ten types of cancers was predicted using BLAST and FASTA format. Small cell lung cancer RB(retinoblastoma1),PTEN(phosphatase and tensin homolog).
Docking methodology 2.2.1 ArgusLab
Argus Lab is docking software that was implemented with shape-based search algorithm using "Argus Dock" exhaustive search docking function of ArgusLab consisting of grid resolution of 20Å. The ligand and binding site groups were created using 910GOL. Then the 3D structure of violacein is opened in the ArgusLab that is then introduced and docking calculation was allowed to run using shape-based search algorithm and scoring function (Fig 2) . Docking was performed for cancer causing proteins in all ten categories of cancers with violacein. 
SwissDock
Desirable protein and ligand were selected to perform docking studies in SwissDock. The resultant was shown in the (Fig 3) . Cancer protein receptors of Ten types of cancers were docked with Violacein ligand. The ligand pose energy values of all the poses of protein was retervied and the best ligand pose energy value was selected 
III. Results and Discussion
Structure similarity studies
BLAST was used to identify the structural similarity of the proteins that were causing cancer. This enables to dock the proteins with the best suitable drug. Seventeen types of proteins that are responsible for ten types of cancers were evaluated for their structural similarity the results of which are shown in Fig 4. Note: No indicates no acceptable ligand pose.
Fig 4 Protein structural similarity of different cancer causing proteins
Among all the proteins under study, maximum structural similarity was seen between the protein receptors PU1 and p53 of 75% identity and between RB and FGFR, with 71% similarity.
Docking Studies:
In the docking study with Argus lab it is observed that violacein had exhibited best binding pose with FLT3 of (-9.16 Kcal/mol) that causes acute myeloid leukemia followed by Beta-catenine (-8.57 Kcal/mol) and k-Ras of (-8.18 Kcal/mol). Among all the cancer causing proteins under stud with violacein, it has exhibited good binding property to most of the proteins except for those causing prostate cancer.
SwissDock results:
From the ArgusLab it is clearly seen that Violacein has exhibited good binding properties. So it is considered for the SwissDock study. The results were tabulated in table along with the comparison with that of the ArgusLab results in (Table 2) . Though the results between the ArgusLab and SwissDock vary in terms of the binding affinity, Violacein has exhibited maximum binding property with 11 proteins that are responsible for 9 cancers
IV. Conclusion
The proteins under study though have exhibited very less structural similarity, and yet all of them have shown some affinity for violacein. Docking studies with the ArgusLab and SwissDock revealed that it has affinity with many proteins that are responsible for causing cancers like colorectal cancer, pancreatic cancer, thyroid cancer and endometrial cancer indicate its potential application as a broad range anti-cancerous drug.
